1. Clinical course of COVID-19 among immunocompromised children: a clinical case series
- Author
-
Huda El Dannan, Moza Al Hassani, and Musaab Ramsi
- Subjects
Male ,0301 basic medicine ,Pediatrics ,medicine.medical_specialty ,Coronavirus disease 2019 (COVID-19) ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,Pneumonia, Viral ,Disease ,Severe Acute Respiratory Syndrome ,infectious diseases ,Risk Assessment ,Severity of Illness Index ,Asymptomatic ,Sampling Studies ,immunology ,paediatrics ,Immunocompromised Host ,03 medical and health sciences ,Sex Factors ,0302 clinical medicine ,030225 pediatrics ,Severity of illness ,Humans ,Medicine ,Viral shedding ,Child ,Pandemics ,business.industry ,Age Factors ,Clinical course ,COVID-19 ,General Medicine ,Prognosis ,Combined Modality Therapy ,Treatment Outcome ,030104 developmental biology ,Child, Preschool ,Female ,medicine.symptom ,Coronavirus Infections ,business ,Risk assessment ,New Disease - Abstract
Infection with SARS-CoV-2 represents a great source of concern and a new threat for immunocompromised patients. Limited studies are available on COVID-19 in immunocompromised children. This case series aimed to evaluate the clinical and laboratory characteristics, management and outcomes of COVID-19 in five children immunocompromised due to different underlying conditions. All had mild symptoms or were asymptomatic at presentation. All had a benign course of illness. No changes or delays in their treatment regimens occurred, and none experienced a relapse of the original disease, developed severe COVID-19 or died. However, these cases showed a prolonged duration of virus shedding. This report suggests that immunocompromised paediatric patients may not be at a higher risk of developing severe COVID-19. However, further studies are required to elaborate on the pathogenesis of COVID-19 in this vulnerable group.
- Published
- 2020
- Full Text
- View/download PDF